NeOnc Technologies Holdings Inc

[NeOnc Technologies Holdings Inc @NeOncTechInc]

NeOnc is pleased to share that Maxim Group has initiated coverage with a Buy rating and a $20 price target in its analyst report!

We are proud to see continued recognition of our mission to advance innovative therapies for patients facing some of the most difficult-to-treat brain cancers.

Read the analyst report:
https://t.co/BICHexN7dT

[NeOnc Technologies Holdings Inc @NeOncTechInc]

NeOnc Technologies (Nasdaq: NTHI) CEO Amir Heshmatpour continues to deepen his alignment with shareholders, investing nearly $1M of personal capital over the past year — including $500K+ in recent open-market purchases.

This comes at a pivotal moment for NeOnc, as the company advances toward key clinical and regulatory milestones.

Read the full press release.

https://t.co/4ZmevUd4jK

#NeOnc #NTHI #Biotech #Healthcare #Investing #BrainCancerResearch

[NeOnc Technologies IR @NeOncIR]

NeOnc Technologies $NTHI recently announced approximately $300,000 in open-market stock purchases by Chairman & CEO Amir Heshmatpour, reinforcing management’s alignment with shareholders and confidence in the Company’s long-term strategy.

https://t.co/nlEtQJdSMD

[NeOnc Technologies Holdings Inc @NeOncTechInc]

NeOnc Technologies | One Year on NASDAQ (NTHI) | Progress, Pipeline & What’s Next

One year after NeOnc Technologies' listing on NASDAQ under the ticker NTHI, NeOnc reflects on key clinical and regulatory milestones achieved as a public company.

This video highlights progress across the pipeline, reinforces the company’s strategic positioning, and looks ahead to the next phase of execution, bringing innovative therapies closer to patients who need them most.

https://t.co/dlX0kOFGmy

#NTHI #NeOnc #GBM

[NeOnc Technologies Holdings Inc @NeOncTechInc]

NeOnc Technologies Holdings Inc NTHI will host a live investor conference call and webcast on March 4, 2026 at 6:00 a.m. PT / 9:00 a.m. ET to present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial.

The discussion will include:
• Safety and toxicity findings
• Dose-escalation observations
• Pharmacokinetic data
• Planned regulatory next steps

📅 March 4, 2026
⏰ 6:00 a.m. PT / 9:00 a.m. ET
🔗 Live webcast: https://t.co/57eaK0mzCM

We look forward to sharing these important clinical updates with the investment community.

https://t.co/tDMHzqqvdh

[NeOnc Technologies Holdings Inc @NeOncTechInc]

Top Entrepreneurs Going into 2026 via @USATODAY

We’re thrilled to celebrate our CEO, Amir Heshmatpour, being featured in USA Today’s list of Top Entrepreneurs Going Into 2026 — a testament to visionary leadership and bold innovation shaping the future of biotech.

👏 Congratulations, to Amir & NeOnc! Here’s to a year of breakthrough science, meaningful progress, and continued impact for patients worldwide.

#Leadership #Entrepreneurship #Biotech #Innovation #2026Vision #Neonc

https://t.co/BUL1uDrGNq

[NeOnc Technologies Holdings Inc @NeOncTechInc]

NeOnc has secured a strategic PIPE investment led by a $10M commitment from Cinctive Capital Management, with total gross proceeds expected to reach ~$16M.

This investment reflects strong institutional confidence in NeOnc’s mission, science, and proprietary CNS delivery platforms. It supports the acceleration of clinical programs focused on bypassing the blood-brain barrier to treat CNS cancers.

#NeOnc #NTHI #CNSCancer #BiotechInvesting #ClinicalTrials

https://t.co/hl3JXEqeUX

[NeOnc Technologies Holdings Inc @NeOncTechInc]

This video highlights pediatric DIPG patients in China receiving investigational NEO100-03 intranasal therapy following prior standard treatments.

Their stories underscore the urgent unmet need in pediatric brain cancer and the importance of continued clinical research.
#NeOnc #PediatricCancer #BrainCancerResearch #DIPG #ClinicalResearch

[NeOnc Technologies Holdings Inc @NeOncTechInc]

Updated clinical data for intranasal NEO100 show continued durable responses in recurrent IDH1-mutant astrocytoma 🧠

• 24% radiographic remission
• 44% PFS-6
• 36% alive ≥18 months
• No significant toxicity

A promising step forward for patients with limited options.

Read the full press release below:
https://t.co/t6HLYZKdVN

[NeOnc Technologies Holdings Inc @NeOncTechInc]

NeOnc Technologies (Nasdaq: $NTHI) announces new findings showing that ultrasound enhances the potency of NEO100 in treating primary and metastatic brain tumors.

A breakthrough at the intersection of AI, oncology, and precision medicine.

#NTHI #AIinMedicine #Biotech #CancerResearch #NeOnc #NEO100

https://t.co/MxXuQ5ojag

[NeOnc Technologies Holdings Inc @NeOncTechInc]

🚨 NeOnc completes enrollment in its pivotal NEO100 Phase 2a trial for IDH1-mutant recurrent glioma. Preliminary data coming Q2 2026.

This milestone follows positive results from a 24-patient cohort shared on the Nov. 12 investor call.

https://t.co/EfcJbFt1DD

#NTHI #NEO100 #Biotech #Glioma #CNS

[NeOnc Technologies Holdings Inc @NeOncTechInc]

NeOnc Technologies (NTHI) is honored to announce that His Highness Sheikh Nahyan bin Zayed Al Nahyan has assumed the role of Executive Chairman of NuroMENA, our Middle East subsidiary — marking a new era in UAE–US collaboration against brain cancer. 🇦🇪🇺🇸🧠
https://t.co/ociPVqjA06

[Ishwar K. Puri @ikpuri]

As a Director of the biotech company @NeOncTechInc bringing brain cancer treatments to market, this independent analysis is spot on: (1) "NeOnc is at a key inflection point from a survival story to a growth story" Kudos to the team! https://t.co/WpzpNBuW7t

[Health Uncensored with Dr. Drew @HUwithDrDrew]

The brain has a natural barrier that blocks most drugs from reaching where they are needed. @NeOncTechInc is changing that.

If you missed this episode, you can watch it now at https://t.co/alJFTff3J9.

Follow us and @drdrew to stay on top of everything health.

[NeOnc Technologies Holdings Inc @NeOncTechInc]

We’re going on @HUwithDrDrew! 🎉
📅 Sept 25 | ⏰ Airs nationwide at 8 AM| Lifetime TV

Hear from Dr. Chen (Founder & CEO) & Amir Heshmatpour (President & Executive Chairman) about how @NeOncTechInc is redefining brain cancer treatment.

Plus, Adeline, a remarkable NEO-100 patient, will share her inspiring journey and the impact of NeOnc’s therapies.

📺 Tune in for a powerful conversation of science, hope, and innovation.
#NeOnc #DrDrew #HealthUncensoredwithdrdrew #BrainCancer #CancerCare #Innovation #GBM

[NeOnc Technologies Holdings Inc @NeOncTechInc]

We’re excited to be part of the American Brain Tumor Association 2025 National Conference!

💡 At @NeOncTechInc, we’re driven by innovation and the belief that together we can create better outcomes for patients and their families.

📍 Stop by and visit us at the event!

#BTSM #braintumor #braincancer #GBM #Glioblastoma #GlioblastomaAwareness #Meningioma #BrainMets #clinicaltrials #ABTANationalConference2025 #BrainTumorStrong #PatientSupport

[Kenny Polcari @KennyPolcari]

In the latest episode of Trader Talk @YahooFinance , I speak with Amir Heshmatpour, executive chairman and president of NeOnc Technologies $NTHI. Amir explains NeOnc’s focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC’s medical school, and how global clinical trials are expanding the company’s reach. It’s a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage.
https://t.co/oTkF9tFx44

[NeOnc Technologies Holdings Inc @NeOncTechInc]

💡 Innovating Treatment. Improving Lives.
At NeOnc Technologies, we’re pushing boundaries with intranasal therapies that overcome the blood-brain barrier���targeting brain tumors like GBM, meningioma, and high-grade gliomas.
⁠
🔬 Now enrolling for clinical trials:
• NEO100 for GBM, meningioma, and pediatric glioma
• NEO212 for brain metastasis
https://t.co/DjpbdZ5FyM
#GBM #NBTS #BTSM #clinicaltrials #braintumor #braincancer #Meningioma #BrainMets @theABTA @NeOncTechInc